QED Therapeutics Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • QED Therapeutics's estimated annual revenue is currently $5.7M per year.(i)
  • QED Therapeutics received $65.0M in venture funding in January 2018.
  • QED Therapeutics's estimated revenue per employee is $77,500
  • QED Therapeutics's total funding is $65M.

Employee Data

  • QED Therapeutics has 74 Employees.(i)
  • QED Therapeutics grew their employee count by -11% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





QED Therapeutics News

2022-04-17 - HER2 negative Breast Cancer Pipeline Insights | Research Report 2022 by DelveInsight

... HER2 negative Breast Cancer treatment therapies, as per DelveInsight ... QED Therapeutics, Inc., Tyme, Inc., PIQUR Therapeutics, Pfizer,...

2019-09-05 - BridgeBio Launches New Subsidiary to Tackle Limb-Girdle ...

Sarepta Therapeutics is also focused on the disease. ... comes about a year after BridgeBio launched QED Therapeutics to develop infigratinib, ...

2019-06-03 - QED Therapeutics Presents New Data on the Potential for ...

SAN FRANCISCO, June 3, 2019 /PRNewswire/ -- QED Therapeutics announced today the presentation of data demonstrating the clinical ...

2019-04-01 - Preclinical Data Demonstrates the Potential of QED ...

SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- QED Therapeutics announced today the presentation of preclinical data demonstrating the ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

QED Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-01-31$65.0MUndisclosedBridgeBio PharmaArticle